-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Initiates Coverage On Immix Biopharma with Buy Rating, Announces Price Target of $21

Benzinga·07/22/2026 11:17:11
語音播報
Needham analyst Gil Blum initiates coverage on Immix Biopharma (NASDAQ:IMMX) with a Buy rating and announces Price Target of $21.